Sommario:Wockhardt shares surged by 14% today. How is it placed in the Pharma sector now
Wockhardt (NS:) shares jumped by 14% today as it completed the phase-3 pneumonia study of macrolide antibiotic Nafithromycin. However, if we talk about the valuations, as per InvestingPro+ some other companies in the Pharma sector may have more upside potential now. According to the Compare feature of InvestingPro+, Zydus Lifesciences Ltd (NS:) and Biocon (NS:) are attractively placed with potential upside of 24% and 21% respectively. Wockhardt, according to InvestingPro+ may have crossed its intrinsic value to be in the overvalued region now.
Disclaimer:
Le opinioni di questo articolo rappresentano solo le opinioni personali dell’autore e non costituiscono consulenza in materia di investimenti per questa piattaforma. La piattaforma non garantisce l’accuratezza, la completezza e la tempestività delle informazioni relative all’articolo, né è responsabile delle perdite causate dall’uso o dall’affidamento delle informazioni relative all’articolo.
IG
BBI Trading
GRIC FX
FXTM
TMGM
OSIRIS FOREX
IG
BBI Trading
GRIC FX
FXTM
TMGM
OSIRIS FOREX
IG
BBI Trading
GRIC FX
FXTM
TMGM
OSIRIS FOREX
IG
BBI Trading
GRIC FX
FXTM
TMGM
OSIRIS FOREX